185O Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): A detailed safety analysis of the randomized, phase III DESTINY-Breast04 trial

Rugo, HS; Jacot, William; Tokunaga, Eriko; Sohn, Joohyuk; Cardoso, Fátima; Xu, Binghe; Vidal, María; Gil, Miguel; Ueno, Naoto T.; Prat, Aleix; Moore, Halle C. F.; Hasler-Strub, Ursula; Cameron, David; Lindman, Henrik; Mezei, K.; Rajagopalan, Rajaganesh; Orbegoso, Cecilia; Cheng, F-C.; Puri, Adeep; Modi, Shanu

doi:10.1016/j.esmoop.2023.101374

Search citation statements

Order By: Relevance

Paper Sections

Select...

Trastuzumab-deruxtecan (T-dxd) In Hr + Bc1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data were also published regarding the subgroup of patients with low ER expression (1-10%). Patients treated with T-DXd had better PFS (mPFS, 8.4 months vs. 2.6 months; HR 0.24 [95% CI, 0.12-0.48]) and OS (HR 0.35 [95% CI, 0.16-0.75]) vs. the chemotherapy group, with a safety profile consistent with primary analyses [39].…”

Section: Trastuzumab-deruxtecan (T-dxd) In Hr + Bcsupporting

confidence: 62%

Antibody–Drug Conjugates in HR+ Breast Cancer: Where Are We Now and Where Are We Heading?

De Santis,

Sanna,

Perrone

et al. 2023

JCM

View full text Add to dashboard Cite

Hormone receptor-positive (HR+) breast cancer (BC) accounts for about 60–70% of all diagnosed BCs, and endocrine therapy has long been the hallmark of systemic treatment for this tumor subtype. However, the therapeutic paradigm of luminal BC has been overcome due to recent evidence of antibody–drug conjugate (ADC) activity (such as trastuzumab deruxtecan and sacituzumab govitecan) in pretreated metastatic HR+ BC patients. Therefore, nowadays, the identification of patients who can benefit more from this approach represents a new challenge, as does the management of new toxicities and the integration of these drugs into the therapeutic algorithm of HR+ metastatic BC patients.

show abstract

Section: Trastuzumab-deruxtecan (T-dxd) In Hr + Bcsupporting

confidence: 62%